Advertisement

Topics

Catalent to Provide Fill & Finish Services for Samsung Bioepis' Biosimilar

10:41 EDT 19 Oct 2016 | PharmPro

Catalent Pharma Solutions has announced that it is to provide fill-finish production services for the commercial supply of SB4, a biosimilar referencing Enbrel.
Contributed Author: 
Catalent
Topics: 

Original Article: Catalent to Provide Fill & Finish Services for Samsung Bioepis' Biosimilar

NEXT ARTICLE

More From BioPortfolio on "Catalent to Provide Fill & Finish Services for Samsung Bioepis' Biosimilar"

Quick Search
Advertisement
 

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...